You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Liu Y, Jiang B, Zhang T, et al
699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0699